Singapore markets closed

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
306.50-2.91 (-0.94%)
At close: 04:00PM EDT
307.50 +1.00 (+0.33%)
Pre-market: 08:30AM EDT

Amgen Inc.

One Amgen Center Drive
Thousand Oaks, CA 91320-1799
United States
805 447 1000
https://www.amgen.com

Sector(s)Healthcare
IndustryDrug Manufacturers - General
Full-time employees26,700

Key executives

NameTitlePayExercisedYear born
Mr. Robert A. BradwayChairman, CEO & President6.73MN/A1963
Mr. Peter H. GriffithExecutive VP & CFO3.07MN/A1959
Mr. Esteban SantosExecutive Vice President of Operations3.01MN/A1968
Dr. David M. Reese M.D.Executive VP & Chief Technology Officer3.4MN/A1963
Mr. Murdo GordonExecutive Vice President of Global Commercial Operations3.24MN/A1967
Mr. Matthew C. BuschChief Accounting Officer & VP of FinanceN/AN/A1974
Mr. Mike ZahigianSenior VP & Chief Information OfficerN/AN/AN/A
Dr. James E. Bradner M.D.Executive VP of Research and Development & Chief Scientific OfficerN/AN/A1972
Justin G. ClaeysVice President of Investor RelationsN/AN/AN/A
Mr. Jonathan P. GrahamExecutive VP, General Counsel & Secretary2.44MN/A1961
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Corporate governance

Amgen Inc.’s ISS governance QualityScore as of 1 May 2024 is 2. The pillar scores are Audit: 2; Board: 9; Shareholder rights: 1; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.